In QuotedData’s morning briefing 10 November 2021:
- Syncona (SYNC) portfolio company Freeline Therapeutics Holdings has announced new data from its ongoing Phase I/II MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease. According to the clincical-stage biotech company, a second patient dosed in Phase I/II trial for Fabry disease has generated encouraging data and remains off enzyme replacement therapy more than 16 weeks post-dosing while a first patient shows durable expression of the key enzyme (α-Gal A), which is absent or markedly deficient in patients, over two years with promising efficacy. Chris Hollowood, CIO of Syncona Investment Management and chair of Freeline, said: “We are pleased that Freeline has been able to re-initiate clinical studies and are encouraged by the data generated by the second patient dosed in the Phase I/II Fabry’s study. We are fully supportive of the safety protocols recommended by the data monitoring committee and look forward to seeing further progress from this study.”
- The scheme of reconstruction of Aberdeen New Thai (ANW) has been approved by shareholders and will see abrdn China (ACIC – formerly Aberdeen Emerging Markets) acquire approximately £62m of net assets from ANW in consideration for the issue of 7,554,440 new ordinary shares in ACIC. A total of 6,894,773 ordinary shares will be repurchased by ACIC today under the tender offer (the tender price is 901.92377 pence per ordinary share) and held in treasury. Mark Hadsley-Chaplin, chairman of ACIC, said: “As of the close of 8th November 2021, the managers have made significant progress in the realignment of the company’s portfolio and around 55% of the portfolio is now exposed to Chinese equities. ACIC expects to receive a further c£62m of assets from Aberdeen New Thai Investment Trust later today and will make a further announcement on the portfolio allocation in the next few days.”
- Picton Property (PCTN) has released half-year results to 30 September 2021, reporting an 8.6% increase in net assets to 105p per share. With dividends, this amounted to a 10.2% NAV total return. The NAV uplift was down to a 7.4% like-for-like portfolio valuation increase in the period. Total dividends for the six months was 1.65p, while EPRA earnings per share was 2.0p.
We also have final results from Aberdeen Latin American Income.